Φορτώνει......
Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part II
Although the hypothesis of benefit from prolonged oral IIb/IIIa inhibition was appealing, the large Phase III trials have uniformly shown there was no improvement in outcome. In addition, there was an increased mortality seen in patients treated with the oral IIb/IIIa inhibitor. This latter finding...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Cardiol |
|---|---|
| Κύριος συγγραφέας: | |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Wiley Periodicals, Inc.
2006
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654522/ https://ncbi.nlm.nih.gov/pubmed/14524594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960260903 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|